Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study

V. Strand, D. van der Heijde, Y. Tanaka, E. Keystone, J. Kremer, CAF. Zerbini, MH. Cardiel, S. Cohen, P. Nash, YW. Song, D. Tegzová, D. Gruben, G. Wallenstein, CA. Connell, R. Fleischmann, ORAL Scan investigators,

. 2020 ; 38 (5) : 848-857. [pub] 20191219

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027872

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) ORAL Scan (NCT00847613), which evaluated the impact of tofacitinib on patient-reported outcomes (PROs) through 24 months in patients with active RA and inadequate responses to methotrexate (MTX-IR). METHODS: Patients were randomised 4:4:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID), or placebo advanced to tofacitinib 5 or 10 mg, plus background MTX. Patients receiving placebo advanced to tofacitinib at month 3 (non-responders) or month 6 (remaining patients). Mean changes from baseline in PROs, assessed at months 1-24, included Health Assessment Questionnaire-Disability Index, Patient Global Assessment of disease activity (visual analogue scale [VAS]), Patient Assessment of Arthritis Pain (VAS), health-related quality of life (Short Form-36 version 2), Functional Assessment of Chronic Illness Therapy-Fatigue and Medical Outcomes Study-Sleep. RESULTS: Overall, 539/797 (67.6%) patients completed 24 months' treatment. At month 3, tofacitinib-treated patients reported signi cant (p<0.05) mean changes from baseline versus placebo across all PROs, and significantly more patients reported improvements ≥ minimum clinically important differences versus placebo. Improvements in PROs with tofacitinib were sustained to month 24. Following advancement to tofacitinib, placebo-treated patients generally reported changes of similar magnitude to tofacitinib-treated patients. CONCLUSIONS: Patients with RA and MTX-IR receiving tofacitinib 5 or 10 mg BID plus MTX reported significant and clinically meaningful improvements in PROs versus placebo at month 3, which were sustained through 24 months.

000      
00000naa a2200000 a 4500
001      
bmc20027872
003      
CZ-PrNML
005      
20210114152528.0
007      
ta
008      
210105s2020 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)31858963
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Strand, Vibeke $u Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA.
245    10
$a Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study / $c V. Strand, D. van der Heijde, Y. Tanaka, E. Keystone, J. Kremer, CAF. Zerbini, MH. Cardiel, S. Cohen, P. Nash, YW. Song, D. Tegzová, D. Gruben, G. Wallenstein, CA. Connell, R. Fleischmann, ORAL Scan investigators,
520    9_
$a OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) ORAL Scan (NCT00847613), which evaluated the impact of tofacitinib on patient-reported outcomes (PROs) through 24 months in patients with active RA and inadequate responses to methotrexate (MTX-IR). METHODS: Patients were randomised 4:4:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID), or placebo advanced to tofacitinib 5 or 10 mg, plus background MTX. Patients receiving placebo advanced to tofacitinib at month 3 (non-responders) or month 6 (remaining patients). Mean changes from baseline in PROs, assessed at months 1-24, included Health Assessment Questionnaire-Disability Index, Patient Global Assessment of disease activity (visual analogue scale [VAS]), Patient Assessment of Arthritis Pain (VAS), health-related quality of life (Short Form-36 version 2), Functional Assessment of Chronic Illness Therapy-Fatigue and Medical Outcomes Study-Sleep. RESULTS: Overall, 539/797 (67.6%) patients completed 24 months' treatment. At month 3, tofacitinib-treated patients reported signi cant (p<0.05) mean changes from baseline versus placebo across all PROs, and significantly more patients reported improvements ≥ minimum clinically important differences versus placebo. Improvements in PROs with tofacitinib were sustained to month 24. Following advancement to tofacitinib, placebo-treated patients generally reported changes of similar magnitude to tofacitinib-treated patients. CONCLUSIONS: Patients with RA and MTX-IR receiving tofacitinib 5 or 10 mg BID plus MTX reported significant and clinically meaningful improvements in PROs versus placebo at month 3, which were sustained through 24 months.
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a revmatoidní artritida $x diagnostické zobrazování $x farmakoterapie $7 D001172
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a lidé $7 D006801
650    _2
$a methotrexát $x terapeutické užití $7 D008727
650    _2
$a hodnocení výsledků péče pacientem $7 D000071066
650    _2
$a piperidiny $7 D010880
650    _2
$a pyrimidiny $7 D011743
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a van der Heijde, Désirée $u Leiden University Medical Center, Leiden, The Netherlands.
700    1_
$a Tanaka, Yoshiya $u First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
700    1_
$a Keystone, Edward $u Mount Sinai Hospital, University of Toronto, Toronto, Canada.
700    1_
$a Kremer, Joel $u Albany Medical College, Albany, NY, USA.
700    1_
$a Zerbini, Cristiano A F $u Centro Paulista de Investigação Clinica, São Paulo, Brazil.
700    1_
$a Cardiel, Mario H $u Centro de Investigacion Clinica de Morelia, Mexico.
700    1_
$a Cohen, Stanley $u Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
700    1_
$a Nash, Peter $u University of Queensland, Australia.
700    1_
$a Song, Yeong-Wook $u Department of Internal Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.
700    1_
$a Tegzová, Dana $u Institute of Rheumatology, Prague, Czech Republic.
700    1_
$a Gruben, David $u Pfizer Inc, Groton, CT, USA.
700    1_
$a Wallenstein, Gene $u Pfizer Inc, Groton, CT, USA. genewallenstein@yahoo.com.
700    1_
$a Connell, Carol A $u Pfizer Inc, Groton, CT, USA.
700    1_
$a Fleischmann, Roy $u Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
710    2_
$a ORAL Scan investigators
773    0_
$w MED00001116 $t Clinical and experimental rheumatology $x 0392-856X $g Roč. 38, č. 5 (2020), s. 848-857
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31858963 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152526 $b ABA008
999    __
$a ok $b bmc $g 1608207 $s 1119052
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 5 $d 848-857 $e 20191219 $i 0392-856X $m Clinical and Experimental Rheumatology $n Clin Exp Rheumatol $x MED00001116
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace